| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802956101064 | 295610106 | ZIPRASIDONE/ACTAVIS CAPS 20MG/CAP BTx56 σε Blisters σε Blisters | 15.77 | 16.54 | 22.79 |
| 05/2018 | 2802956102061 | 295610206 | ZIPRASIDONE/ACTAVIS CAPS 40MG/CAP (Γενοσημου) BTx56 σε Blisters σε Blisters | 22.87 | 23.99 | 33.06 |
| 05/2018 | 2802956103068 | 295610306 | ZIPRASIDONE/ACTAVIS CAPS 60MG/CAP (Γενοσημου) BTx56 σε Blisters σε Blisters | 22.87 | 23.99 | 33.06 |
| 05/2018 | 2802956104065 | 295610406 | ZIPRASIDONE/ACTAVIS CAPS 80MG/CAP (Γενοσημου) BTx56 σε Blisters σε Blisters | 24.85 | 26.07 | 35.92 |
For the treatment of schizophrenia and related psychotic disorders.
Ziprasidone's antipsychotic activity is likely due to a combination of its antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.
~60%
7 hours
Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces.
* 1.5 L/kg
* 7.5 mL/min/kg